Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and/or regionally advanced cutaneous squamous cell carcinoma

Trial Profile

A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and/or regionally advanced cutaneous squamous cell carcinoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2018

At a glance

  • Drugs Carboplatin (Primary) ; Durvalumab (Primary)
  • Indications Skin cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CRIO
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top